Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study

Prostate Cancer and Prostatic Diseases volume 20, pages 328–333 (2017)Cite this article

Subjects

Abstract

Background:

Clinical observations indicated an increased risk of developing prostate cancer in gout patients. Chronic inflammation is postulated to be one crucial mechanism for prostate carcinogenesis. Allopurinol, a widely used antigout agent, possesses potent anti-inflammation capacity. We elucidated whether allopurinol decreases the risk of prostate cancer in gout patients.

Methods:

We analyzed data retrieved from Taiwan National Health Insurance Database between January 2000 and December 2012. Patients diagnosed with gout during the study period with no history of prostate cancer and who had never used allopurinol were selected. Four allopurinol use cohorts (that is, allopurinol use (>365 days), allopurinol use (181–365 days), allopurinol use (91–180 days) and allopurinol use (31–90 days)) and one cohort without using allopurinol (that is, allopurinol use (No)) were included. The study end point was the diagnosis of new-onset prostate cancer. Multivariable Cox proportional hazards regression and propensity score-adjusted Cox regression models were used to estimate the association between the risk of prostate cancer and allopurinol treatment in gout patients after adjusting for potential confounders.

Results:

A total of 25 770 gout patients (aged between 40 and 100 years) were included. Multivariable Cox regression analyses revealed that the risk of developing prostate cancer in the allopurinol use (>365 days) cohort was significantly lower than the allopurinol use (No) cohort (adjusted hazard ratio (HR)=0.64, 95% confidence interval (CI)=0.45–0.9, P=0.011). After propensity score adjustment, the trend remained the same (adjusted HR=0.66, 95% CI=0.46–0.93, P=0.019).

Conclusions:

Long-term (more than 1 year) allopurinol use may associate with a decreased risk of prostate cancer in gout patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Bardin T, Richette P . Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014; 26: 186–191.

    Article  CAS  Google Scholar 

  2. Singh JA . Gout: will the "King of Diseases" be the first rheumatic disease to be cured? BMC Med 2016; 14: 180.

    Article  Google Scholar 

  3. Kienhorst LB, van Lochem E, Kievit W, Dalbeth N, Merriman ME, Phipps-Green A et al. Gout is a chronic inflammatory disease in which high levels of interleukin-8 (CXCL8), myeloid-related protein 8/myeloid-related protein 14 complex, and an altered proteome are associated with diabetes mellitus and cardiovascular disease. Arthritis Rheumatol 2015; 67: 3303–3313.

    Article  CAS  Google Scholar 

  4. Wang W, Xu D, Wang B, Yan S, Wang X, Yin Y et al. Increased risk of cancer in relation to gout: a review of three prospective cohort studies with 50,358 subjects. Mediators Inflamm 2015; 2015: 680853.

    PubMed  PubMed Central  Google Scholar 

  5. Chen CJ, Yen JH, Chang SJ . Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol 2014; 43: 385–390.

    Article  Google Scholar 

  6. Kuo CF, Luo SF, See LC, Chou IJ, Fang YF, Yu KH . Increased risk of cancer among gout patients: a nationwide population study. Joint Bone Spine 2012; 79: 375–378.

    Article  Google Scholar 

  7. Boffetta P, Nordenvall C, Nyren O, Ye W . A prospective study of gout and cancer. Eur J Cancer Prev 2009; 18: 127–132.

    Article  Google Scholar 

  8. Pacher P, Nivorozhkin A, Szabo C . Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58: 87–114.

    Article  CAS  Google Scholar 

  9. Park JJ, Roudier MP, Soman D, Mokadam NA, Simkin PA . Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study. BMJ Open 2014; 4: e005308.

    Article  Google Scholar 

  10. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256–269.

    Article  CAS  Google Scholar 

  11. Yasuda T, Yoshida T, Goda AE, Horinaka M, Yano K, Shiraishi T et al. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Res 2008; 6: 1852–1860.

    Article  CAS  Google Scholar 

  12. Kimura T . East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer 2012; 31: 421–429.

    Article  CAS  Google Scholar 

  13. Hung CF, Yang CK, Ou YC . Urologic cancer in Taiwan. Jpn J Clin Oncol 2016; 46: 605–609.

    Article  Google Scholar 

  14. Sun LM, Lin MC, Lin CL, Chang SN, Liang JA, Lin IC et al. Statin use reduces prostate cancer all-cause mortality: a nationwide population-based cohort study. Medicine (Baltimore) 2015; 94: e1644.

    Article  CAS  Google Scholar 

  15. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML . Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20: 236–242.

    Article  Google Scholar 

  16. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF . Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900.

    Article  CAS  Google Scholar 

  17. Yu TM, Chuang YW, Yu MC, Chen CH, Yang CK, Huang ST et al. Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study. Lancet Oncol 2016; 17: 1419–1425.

    Article  Google Scholar 

  18. Ozbek E, Otunctemur A, Dursun M, Sahin S, Besiroglu H, Koklu I et al. Diabetes mellitus and HbA1c levels associated with high grade prostate cancer. Asian Pac J Cancer Prev 2014; 15: 2555–2558.

    Article  Google Scholar 

  19. Banez LL, Loftis RM, Freedland SJ, Presti JC Jr, Aronson WJ, Amling CL et al. The influence of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis 2010; 13: 173–177.

    Article  CAS  Google Scholar 

  20. Liang Z, Xie B, Li J, Wang X, Wang S, Meng S et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep 2016; 6: 31358.

    Article  CAS  Google Scholar 

  21. Hayashi N, Matsushima M, Yamamoto T, Sasaki H, Takahashi H, Egawa S . The impact of hypertriglyceridemia on prostate cancer development in patients aged >/=60 years. BJU Int 2012; 109: 515–519.

    Article  Google Scholar 

  22. Solomon KR, Freeman MR . The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am 2011; 38: 243–259.

    Article  Google Scholar 

  23. Thakur H, Gupta L, Sobti RC, Janmeja AK, Seth A, Singh SK . Association of GSTM1T1 genes with COPD and prostate cancer in north Indian population. Mol Biol Rep 2011; 38: 1733–1739.

    Article  CAS  Google Scholar 

  24. Vidal AC, Freedland SJ . Obesity and prostate cancer: a focused update on active surveillance, race, and molecular subtyping. Eur Urol 2016 (e-pub ahead of print 10 October 2016; doi:10.1016/j.eururo.2016.10.011).

  25. Hamilton Z, Parsons JK . Prostate cancer prevention: concepts and clinical trials. Curr Urol Rep 2016; 17: 35.

    Article  Google Scholar 

  26. Huang TB, Yan Y, Guo ZF, Zhang XL, Liu H, Geng J et al. Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol 2014; 46: 1715–1728.

    Article  CAS  Google Scholar 

  27. Sangkop F, Singh G, Rodrigues E, Gold E, Bahn A . Uric acid: a modulator of prostate cells and activin sensitivity. Mol Cell Biochem 2016; 414: 187–199.

    Article  CAS  Google Scholar 

  28. Kuo CF, Grainge MJ, See LC, Yu KH, Luo SF, Zhang W et al. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther 2015; 17: 13.

    Article  Google Scholar 

  29. Kuo CF, Grainge MJ, Zhang W, Doherty M . Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 2015; 11: 649–662.

    Article  Google Scholar 

  30. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG . Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 267–272.

    Article  CAS  Google Scholar 

  31. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M . Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015; 74: 661–667.

    Article  Google Scholar 

  32. Battelli MG, Polito L, Bortolotti M, Bolognesi A . Xanthine oxidoreductase in cancer: more than a differentiation marker. Cancer Med 2016; 5: 546–557.

    Article  CAS  Google Scholar 

  33. Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi H . Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis 2014; 73: 385–390.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan

    H-J Shih

  2. School of Medicine, Chung Shan Medical University, Taichung, Taiwan

    H-J Shih

  3. School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

    H-J Shih

  4. Department of Anesthesiology, Taipei Tzu Chi Hospital, Taipei, Taiwan

    M-C Kao, Y-C Fan & C-J Huang

  5. School of Medicine, Tzu Chi University, Hualien, Taiwan

    M-C Kao & C-J Huang

  6. Graduate Institute of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan

    P-S Tsai

Authors
  1. H-J Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M-C Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P-S Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y-C Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C-J Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C-J Huang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shih, HJ., Kao, MC., Tsai, PS. et al. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study. Prostate Cancer Prostatic Dis 20, 328–333 (2017). https://doi.org/10.1038/pcan.2017.14

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2017.14

This article is cited by

Search

Advanced search

Quick links